Lazabemide
Lazabemide
Lazabemide (pronounced: la-za-be-mide) is a monoamine oxidase B (MAO-B) inhibitor that was primarily developed for the treatment of Parkinson's disease. It was discovered and developed by Roche, a Swiss multinational healthcare company.
Etymology
The term "Lazabemide" is a coined name, like many pharmaceutical drugs. The exact etymology is not known, but it is likely that the name was derived from the chemical structure or the pharmacological properties of the drug.
Pharmacology
Lazabemide is a selective and reversible inhibitor of the enzyme monoamine oxidase B. This enzyme is responsible for the breakdown of dopamine in the brain. By inhibiting this enzyme, Lazabemide increases the levels of dopamine in the brain, which can help to alleviate the symptoms of Parkinson's disease.
Clinical Use
Lazabemide was primarily developed for the treatment of Parkinson's disease. However, it has also been investigated for potential use in the treatment of other conditions, such as Alzheimer's disease and depression.
Related Terms
See Also
External links
- Medical encyclopedia article on Lazabemide
- Wikipedia's article - Lazabemide
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski